

- 4 Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007;356:2271–2281.
- 5 Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, Sinescu IC: Renal cell carcinoma guideline. *Eur Urol* 2007;51:1502–1510.
- 6 Di Silverio F, Sciarra A, Parente U, Andrea A, Von Heland M, Panebianco V, Passariello R: Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. *Urol Int* 2008;80:451–453.
- 7 Hackenberg OW: Comment on Di Silverio et al: Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. *Urol Int* 2008;80:451–453. *Urol Int* 2008;80:454.
- 8 Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. *J Urol* 2009;181:518–523.
- 9 Shuch B, Riggs SB, LaRochelle JC, Kabbavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS: Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. *BJU Int* 2008;102:692–696.
- 10 Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. *J Urol* 2008;180:94–98.
- 11 Robert G, Gabbay G, Bram R, Wallerand H, Deminiere C, Cornelis F, Bernhard JC, Ravaud A, Ballanger P: Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. *Eur Urol* 2009;55:1477–1480.
- 12 Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J: Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. *World J Urol* 2009;27:533–539.
- 13 Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H: The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. *BJU Int* 2004;94:33–41.
- 14 Boorjian SA, Sengupta S, Blute ML: Renal cell carcinoma: vena caval involvement. *BJU Int* 2007;99:1239–1244.
- 15 van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E: Sunitinib for treatment of advanced renal cell cancer: primary tumor response. *Clin Cancer Res* 2008;14:2431–2436.
- 16 Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X: Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. *Recent Pat Anti-cancer Drug Discov* 2007;2:59–71.
- 17 Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. *J Transl Med* 2007;5:32.

Retraction of Authorship

Please note: Due to an error which occurred during the publication process of the article Yuan M, Shi B-Y, Li H-Z, Xia M, Han Y, Xu X-G, Zhang Y-S: De novo Urothelial Carcinoma in Kidney Transplantation Patients with End-Stage Aristolochic Acid Nephropathy in China, *Urol Int* 2009;83:200–205, M. Yuan and B.-Y. Shi have submitted a signed statement of withdrawal and no longer wish their names to be connected with the paper.